| __timestamp | Novo Nordisk A/S | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 26760000000 | 10811000 |
| Thursday, January 1, 2015 | 32169000000 | 33001000 |
| Friday, January 1, 2016 | 32339000000 | 64936000 |
| Sunday, January 1, 2017 | 32124000000 | 99909000 |
| Monday, January 1, 2018 | 33313000000 | 127724000 |
| Tuesday, January 1, 2019 | 35830000000 | 161524000 |
| Wednesday, January 1, 2020 | 36886000000 | 182933000 |
| Friday, January 1, 2021 | 41058000000 | 219982000 |
| Saturday, January 1, 2022 | 50684000000 | 278139000 |
| Sunday, January 1, 2023 | 61598000000 | 309799000 |
| Monday, January 1, 2024 | 67377000000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Novo Nordisk A/S and Ultragenyx Pharmaceutical Inc. offer a fascinating study in contrasts. Over the past decade, Novo Nordisk has consistently maintained a robust SG&A strategy, with expenses growing from approximately 27 billion in 2014 to 62 billion in 2023, reflecting a strategic expansion. In contrast, Ultragenyx's SG&A expenses have increased from a modest 11 million to 310 million over the same period, indicating a more cautious growth trajectory. While Novo Nordisk's expenses have surged by over 130%, Ultragenyx has seen a staggering increase of nearly 2700%, albeit from a much smaller base. This data highlights the differing scales and strategies of these two companies, offering insights into their operational efficiencies and market approaches.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Johnson & Johnson
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Intra-Cellular Therapies, Inc.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Biogen Inc.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Madrigal Pharmaceuticals, Inc.
Novo Nordisk A/S and Walgreens Boots Alliance, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Novo Nordisk A/S vs Jazz Pharmaceuticals plc
Novo Nordisk A/S vs Grifols, S.A.: SG&A Expense Trends
Lantheus Holdings, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Alpine Immune Sciences, Inc. and Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Ultragenyx Pharmaceutical Inc. or Geron Corporation